Newland Pharmaceutical Full Year 2024 Earnings: EPS: CN¥0.62 (vs CN¥0.56 in FY 2023)

Simply Wall St · 03/11 22:33

Newland Pharmaceutical (SZSE:301277) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥726.4m (up 12% from FY 2023).
  • Net income: CN¥173.6m (up 9.2% from FY 2023).
  • Profit margin: 24% (in line with FY 2023).
  • EPS: CN¥0.62 (up from CN¥0.56 in FY 2023).
earnings-and-revenue-history
SZSE:301277 Earnings and Revenue History March 11th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Newland Pharmaceutical shares are up 8.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Newland Pharmaceutical (1 is potentially serious!) that you need to take into consideration.